Corcept Therapeutics Incorporated (NASDAQ: CORT) Long Term Investor Alert: Investigation of potential Wrongdoing

An investigation on behalf of current long-term investors in shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) concerning potential breaches of fiduciary duties by certain directors and officers of Corcept Therapeutics Incorporated was announced.

Investors who are current long term investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: CORT stocks follows a lawsuit filed against Corcept Therapeutics Incorporated over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CORT stocks, concerns whether certain Corcept Therapeutics Incorporated directors are liable in connection with the allegations made in that lawsuit.

Redwood City, CA based Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as "Cushing's syndrome").
Corcept Therapeutics Incorporated (NASDAQ: CORT) reported that its annual Total Revenue rose from $482.37 million in 2023 to $675.04 million in 2024, and that its Net Income increased from $106.14 million in 2023 to $141.2 million in 2024.

On December 31, 2025, Corcept Therapeutics Incorporated revealed that the FDA had issued a Complete Response Letter ("CRL") regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had "concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness."

On January 30, 2026, the FDA published a redacted copy of the CRL. The CRL detailed the FDA's concerns with the relacorilant NDA, including concerns that the clinical studies that were submitted as part of the NDA were not sufficient evidence of relacorilant's efficacy for the proposed indication. The CRL also noted that, during pre-submission meetings, the FDA informed Corcept "on several occasions" of its "concerns about the adequacy of the clinical development program," and had warned the Company "to expect significant review issues," if it submitted the application.

Shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) declined from as high as $117.33 per share on March 31, 2025, to as low as $32.99 per share on December 31, 2025.

According to that complaint filed in the U.S. District Court for the Northern District of California that the Defendants represented that the key clinical trials supporting the use of relacorilant as treatment for patients with hypercortisolism were "powerful support" for the New Drug Application ("NDA") that Corcept submitted to the U.S. Food and Drug Administration ("FDA") for this indication, that the defendants also stated that they had communicated with the FDA about this NDA and were confident in submitting the NDA, foreseeing no impediments to approval. Toward the latter part of the Class Period, Defendants repeatedly told investors that "relacorilant is approaching approval", and that in truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the relacorilant NDA and, as a result, there was a known material risk that Corcept's relacorilant NDA would not be approved.

Those who purchased shares of Corcept Therapeutics Incorporated (NASDAQ: CORT) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.